PERCUTANEOUS CLOSURE OF PATENT DUCTUS ARTERIOSUS; IMPLICATIONS OF THE KRICHENKO CLASSIFICATION

Intravenous Paracetamol and Patent Ductus Arteriosus Closure

Background: Standard medical treatments for patent ductus arteriosus (PDA) closure are, including indomethacin/ibuprofen and surgical ligation. Nowadays, a new strategy to close PDA is the use of paracetamol. The present study aimed to describe the use of intravenous (IV) paracetamol for PDA closure in neonates who present a contraindication to ibuprofen or ibuprofen failure with no possibility...

Closure of Small Patent Ductus Arteriosus by Occluding Detachable Coil

Percutaneous closure of patent ductus arteriosus in an asymptomatic adult.

T he ductus arteriosus allows deoxygenated blood from the right ventricle through the descending aorta and to the placenta in the fetal period. Functional and anatomical closure is complete by several weeks after birth. Patients with ductus-dependent physiology generally have advanced congenital malformations and require surgical intervention early in life. However, some patients will present a...

Percutaneous closure of patent ductus arteriosus in preterm infants.

Patent ductus arteriosus (PDA) is found in more than 60% of preterm infants born at a gestational age of less than 28 weeks.1,2 The therapeutic approach to PDA consists of medical treatment with indomethacin or ibuprofen, and surgical ligation or stapling as salvage therapy. Surgery is not free of complications,2-4 with a mortality risk that ranges between 1% and 10%.2,5,6 We present the case o...

Transcatheter closure of the patent ductus arteriosus.

Patent ductus arteriosus (PDA) is one of the most common congenital heart defects. Although surgery is still required in symptomatic neonates, the majority of older infants and children can undergo safe and effective transcatheter device closure on an out-patient basis. First described in 1967, over the past four decades, numerous devices have been specifically developed for this purpose. This ...